Belpointe Asset Management LLC Sells 9,819 Shares of Pfizer Inc. $PFE

Belpointe Asset Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 7.5% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 120,284 shares of the biopharmaceutical company’s stock after selling 9,819 shares during the quarter. Belpointe Asset Management LLC’s holdings in Pfizer were worth $2,916,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new stake in Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Horizon Financial Services LLC bought a new position in Pfizer in the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Stock Performance

NYSE PFE opened at $26.45 on Tuesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market cap of $150.38 billion, a P/E ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55. The company’s 50-day simple moving average is $24.72 and its 200 day simple moving average is $24.12.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.